Recent advances in understanding hereditary spastic paraplegias and emerging therapies - Sorbonne Université
Journal Articles Faculty Reviews Year : 2021

Recent advances in understanding hereditary spastic paraplegias and emerging therapies

Abstract

Hereditary spastic paraplegias (HSPs) are a group of rare, inherited, neurological diseases characterized by broad clinical and genetic heterogeneity. Lower-limb spasticity with first motoneuron involvement is the core symptom of all HSPs. As spasticity is a syndrome and not a disease, it develops on top of other neurological signs (ataxia, dystonia, and parkinsonism). Indeed, the definition of genes responsible for HSPs goes beyond the 79 identified SPG genes. In order to avoid making a catalog of the different genes involved in HSP in any way, we have chosen to focus on the HSP with cerebellar ataxias since this is a frequent association described for several genes. This overlap leads to an intermediary group of spastic ataxias which is actively genetically and clinically studied. The most striking example is SPG7, which is responsible for HSP or cerebellar ataxia or both. There are no specific therapies against HSPs, and there is a dearth of randomized trials in patients with HSP, especially on spasticity when it likely results from other mechanisms. Thus far, no gene-specific therapy has been developed for HSP, but emerging therapies in animal models and neurons derived from induced pluripotent stem cells are potential treatments for patients.
Fichier principal
Vignette du fichier
article.pdf (2.29 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03190639 , version 1 (06-04-2021)

Identifiers

Cite

Pauline Lallemant-Dudek, Frédéric Darios, Alexandra Durr. Recent advances in understanding hereditary spastic paraplegias and emerging therapies. Faculty Reviews, 2021, 10, ⟨10.12703/r/10-27⟩. ⟨hal-03190639⟩
19 View
138 Download

Altmetric

Share

More